Literature DB >> 11261785

Alternative versus classical macrophage activation during experimental African trypanosomosis.

B Namangala1, P De Baetselier, W Noël, L Brys, A Beschin.   

Abstract

The type I/type II cytokine balance may influence the development of different subsets of suppressive macrophages, i.e., classically activated macrophages (caMphi, type I) versus alternatively activated macrophages (aaMphi, type II). Recently, we showed that although mice infected with phospholipase C-deficient (PLC-/-) Trypanosoma brucei brucei exhibit a clear shift from type I to the type II cytokine production, wild type (WT)-infected mice remain locked in a type I cytokine response. In the present study, phenotype and accessory cell function of macrophages elicited during WT and PLC-/- T. b. brucei infection were compared. Results indicate that caMphi develop in a type I cytokine environment in the early phase of WT and PLC-/- trypanosome infection, correlating with inhibition of T cell activation triggered by a mitogen, a superantigen, or an antigen. In the late stage of infection, only PLC(-/-)-infected mice resisting the infection develop type II cytokine-associated aaMphi correlating with impaired antigen- but not mitogen- or superantigen-induced T cell activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11261785

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  18 in total

1.  Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis.

Authors:  Claudia Manca; Michael B Reed; Sherry Freeman; Barun Mathema; Barry Kreiswirth; Clifton E Barry; Gilla Kaplan
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

2.  Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation.

Authors:  A Guerrero; N Jain; X Wang; B C Fries
Journal:  Infect Immun       Date:  2010-01-04       Impact factor: 3.441

3.  Type I IFNs play a role in early resistance, but subsequent susceptibility, to the African trypanosomes.

Authors:  Rebecca Lopez; Karen P Demick; John M Mansfield; Donna M Paulnock
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Immunobiology of African trypanosomes: need of alternative interventions.

Authors:  Toya Nath Baral
Journal:  J Biomed Biotechnol       Date:  2010-02-23

5.  Infection stage-dependent modulation of macrophage activation in Trypanosoma congolense-resistant and -susceptible mice.

Authors:  Wim Noël; Gholamreza Hassanzadeh; Geert Raes; Boniface Namangala; Inge Daems; Lea Brys; Frank Brombacher; Patrick De Baetselier; Alain Beschin
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Effects of exogenous transforming growth factor beta on Trypanosoma congolense infection in mice.

Authors:  Boniface Namangala; Chihiro Sugimoto; Noboru Inoue
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

7.  STAT1 is essential for antimicrobial effector function but dispensable for gamma interferon production during Toxoplasma gondii infection.

Authors:  L Cristina Gavrilescu; Barbara A Butcher; Laura Del Rio; Gregory A Taylor; Eric Y Denkers
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 8.  Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator.

Authors:  Priyanka Das; Amit Lahiri; Ayan Lahiri; Dipshikha Chakravortty
Journal:  PLoS Pathog       Date:  2010-06-17       Impact factor: 6.823

Review 9.  Parasite-driven pathogenesis in Trypanosoma brucei infections.

Authors:  L J Morrison
Journal:  Parasite Immunol       Date:  2011-08       Impact factor: 2.280

10.  Immunophenotypic lymphocyte profiles in human african trypanosomiasis.

Authors:  Caroline Boda; Bertrand Courtioux; Pierre Roques; Lynda Pervieux; Gédéon Vatunga; Théophile Josenando; Constant Roger Ayenengoye; Bernard Bouteille; Marie-Odile Jauberteau; Sylvie Bisser
Journal:  PLoS One       Date:  2009-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.